Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 17:16:1727417.
doi: 10.3389/fphar.2025.1727417. eCollection 2025.

Editorial: Histone modifications in cancer

Jiaqian Luo  1 , Sizhi P Gao  2
Affiliations
Editorial

Editorial: Histone modifications in cancer

Jiaqian Luo et al. Front Pharmacol. .
No abstract available

Keywords: cancer biology; epigenetic therapies; epigenetics; histone modification; methylation; precision oncology; superenhancer; tumor immune microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

    1. El Omari N., Bakrim S., Elhrech H., Aanniz T., Balahbib A., Lee L.-H., et al. (2025). Clinical efficacy and mechanistic insights of FDA-Approved HDAC inhibitors in the treatment of lymphoma. Eur. J. Pharm. Sci., 208, 107057. 10.1016/j.ejps.2025.107057 - DOI - PubMed
    1. Liu Z., Ren Y., Weng S., Xu H., Li L., Han X. (2022). A new trend in cancer treatment: the combination of epigenetics and immunotherapy. Front. Immunol., 13, 809761–2022. 10.3389/fimmu.2022.809761 - DOI - PMC - PubMed
    1. Rodrigues J. A., Luo J., Sabel A. R., Chen Z., Tang X., Kuo F., et al. (2024). Abstract 4366: loss of EP300 triggers IL-1α signaling and subsequent activation of the IL-6/JAK/STAT3 axis to drive oncogenesis in bladder cancer. Cancer Res. 84 (6_Suppl. ment), 4366. 10.1158/1538-7445.Am2024-4366 - DOI
    1. Stief S. M., Hanneforth A.-L., Weser S., Mattes R., Carlet M., Liu W.-H., et al. (2020). Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia 34 (1), 50–62. 10.1038/s41375-019-0497-6 - DOI - PMC - PubMed
    1. Tang M., Gong M., Liu X., Zhang T., Liu Z., Song D. (2025). Recent update on the development of EZH2 inhibitors and degraders for cancer therapy. Eur. J. Med. Chem., 299, 118106. 10.1016/j.ejmech.2025.118106 - DOI - PubMed

Publication types

LinkOut - more resources